ridaforolimus
Small moleculeexperimental
Ridaforolimus is an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. — Wikipedia
Clinical trial activity
37 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
22
Phase 2
14
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2003 (NCT00060632)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Endometrial Neoplasms · Phase 2
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Gliosarcoma · Phase 1
- Healthy Volunteers · Phase 1
- Hematologic Neoplasms · Phase 2
- Hepatic Insufficiency · Phase 1
- Leiomyosarcoma · Phase 2
- Leukemia · Phase 2
- Liposarcoma · Phase 2
- Lymphoma · Phase 2
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 2
- Osteosarcoma · Phase 2
- Ovarian Neoplasms · Phase 1
- Primary Myelofibrosis · Phase 2
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C- Mol. weight
- 990.22 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRidaforolimus ↗
- ChEMBLCHEMBL2103839 ↗
Also known as
- ap23573
- ap23573
- ap23573
- ap23573
- ap-23573
- ap-23573
- ap-23573
- deforolimus
- deforolimus
- deforolimus
- deforolimus
- deforolimus
- jenzyl
- mk8669
- mk 8669
- mk-8669
- mk-8669
- mk-8669
- mk-8669
- ridaforolimus
- ridaforolimus
- ridaforolimus
- ridaforolimus
- ridaforolimus
- ridaforolimus
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03702608 | N/A | Oct 31, 2018 | Medinol |
| NCT01605396 | Phase 2 | Jul 4, 2012 | Merck |
| NCT01431547 | Phase 1 | Feb 1, 2012 | Merck |
| NCT01431534 | Phase 1 | Jan 30, 2012 | Merck |
| NCT01380184 | Phase 1 | Jul 1, 2011 | Merck |
| NCT01256268 | Phase 1 | Jun 13, 2011 | Merck, University of South Florida |
| NCT01296659 | Phase 1 | Feb 1, 2011 | Merck, University of Texas, San Antonio |
| NCT01295632 | Phase 1 | Feb 1, 2011 | Merck |
| NCT01243762 | Phase 1 | Nov 1, 2010 | Merck |
| NCT01169532 | Phase 1 | Oct 1, 2010 | National Cancer Institute (NCI), Temple University |
| NCT01234857 | Phase 2 | Sep 17, 2010 | Merck |
| NCT01220570 | Phase 1 | Sep 1, 2010 | Merck |
| NCT01212627 | Phase 1 | Sep 1, 2010 | Boston University, Brown University, Rhode Island Hospital |
| NCT01071304 | Phase 1 | Mar 1, 2010 | Merck |
| NCT01043887 | Phase 1 | Jan 1, 2010 | Ariad Pharmaceuticals, Merck |
| NCT01010672 | Phase 2 | Nov 1, 2009 | Ariad Pharmaceuticals, Merck |
| NCT00874731 | Phase 1 | Apr 1, 2009 | Merck |
| NCT00818675 | Phase 2 | Mar 1, 2009 | Ariad Pharmaceuticals, Merck |
| NCT00836927 | Phase 2 | Feb 1, 2009 | Ariad Pharmaceuticals, Merck |
| NCT00781846 | Phase 1 | Oct 1, 2008 | Ariad Pharmaceuticals, Merck |
Showing 20 of 37 trials
Page 1 / 2
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 33 | 31 | 3 | 2003 |
| Ariad Pharmaceuticals | For profit | 18 | 0 | 3 | 2003 |
| University of South Florida | Academic/Hospital | 2 | 1 | 1 | 2008 |
| Boston University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Brown University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Medinol | For profit | 1 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2010 |
| Pediatric Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Rhode Island Hospital | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Temple University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2008 |
16 organizations
Page 1 / 1